within Pharmacolibrary.Drugs.ATC.L;

model L01XG03
  extends Pharmacokinetic.Models.PK_3C_enteral(
    weight         = 70,
    F              = 0.58,
    Cl             = 3.1e-05,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.543,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006833333333333333,
    Tlag           = 24.599999999999998
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XG03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>3</td></tr></table><p>Ixazomib is an oral proteasome inhibitor indicated for the treatment of multiple myeloma in combination with lenalidomide and dexamethasone in patients who have received at least one prior therapy. It is approved and currently used for this indication.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with relapsed/refractory multiple myeloma; both sexes; typical age range 40-80 years. Parameters are representative of standard oral administration and are based on published studies.</p><h4>References</h4><ol><li><p>Gupta, N, Hanley, MJ, Venkatakrishnan, K, Perez, R, Norris, RE, Nemunaitis, J, Yang, H, Qian, MG, Falchook, G, Labotka, R, &amp; Fu, S (2016). Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. <i>British journal of clinical pharmacology</i> 82(3) 728–738. DOI:<a href=\"https://doi.org/10.1111/bcp.12991\">10.1111/bcp.12991</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27121262/\">https://pubmed.ncbi.nlm.nih.gov/27121262</a></p></li><li><p>Gupta, N, Hanley, MJ, Xia, C, Labotka, R, Harvey, RD, &amp; Venkatakrishnan, K (2019). Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. <i>Clinical pharmacokinetics</i> 58(4) 431–449. DOI:<a href=\"https://doi.org/10.1007/s40262-018-0702-1\">10.1007/s40262-018-0702-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30117017/\">https://pubmed.ncbi.nlm.nih.gov/30117017</a></p></li><li><p>Gupta, N, Hanley, MJ, Diderichsen, PM, Yang, H, Ke, A, Teng, Z, Labotka, R, Berg, D, Patel, C, Liu, G, van de Velde, H, &amp; Venkatakrishnan, K (2019). Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor. <i>Clinical pharmacology and therapeutics</i> 105(2) 376–387. DOI:<a href=\"https://doi.org/10.1002/cpt.1047\">10.1002/cpt.1047</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29446068/\">https://pubmed.ncbi.nlm.nih.gov/29446068</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XG03;
